share_log

MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published In The Journal Of Clinical Endocrinology And Metabolism

MBXバイオサイエンスは、臨床内分泌代謝ジャーナルに掲載されたMBX 2109のフェーズ1スタディ結果を発表しました。

Benzinga ·  12/02 09:06

MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the publication of a peer-reviewed article highlighting results from the Phase 1 study of MBX 2109, the Company's parathyroid hormone (PTH) peptide prodrug in development for the treatment of hypoparathyroidism (HP). The publication, titled "MBX 2109, a Once-Weekly Parathyroid Hormone Replacement Therapy Prodrug: Phase 1, First-in-Human, Randomized Trial", was published in The Journal of Clinical Endocrinology and Metabolism (JCEM) and can be accessed here.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする